Abstracts

CD161+Vα7.2+IL18R+ MAIT Cells Are Reduced in HIV Infection Regardless of the Disease Status

Background: Mucosal-associated invariant T (MAIT) cells are characterized by the combined expression of the semi-invariant TCR Vα7.2, the lectin receptor CD161 and the IL18 receptor. They play an important role in the antibacterial host defense of the gut. CD161+ MAIT cells vanish almost completely from the bloodstream in HIV-infected patients and cannot be restored by…

Innate Immune Reconstitution with Viral Suppression in HIV-1 Infection

Background: HIV-1 infection leads to both marked immunodeficiency and to dysregulated immune activation and inflammation. Given the broad nature of immune dysfunction and pathogen susceptibility, we hypothesized that HIV-1 viremia would alter innate immune responses, the fundamental mediators of pathogen recognition. Using longitudinal samples collected before and after initiation of antiretroviral therapy (ART), we tested…

Population Surveys: What Do They Show?

Background: Since 2001, a large number of national surveys with measurement of HIV status have been conducted, most of them in sub-Saharan Africa (35 countries), but also in selected countries in Asia (2 countries) and in the Caribbean (2 countries). Many of these surveys are conducted within the Demographic and Health Survey programme, others are…

IFN-free 3 DAA Regimen in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine

Background: ABT-450 is an HCV NS3/4A protease inhibitor (dosed with ritonavir 100mg, ABT-450/r) identified by AbbVie and Enanta. ABT-267 is an NS5A inhibitor, and ABT-333 is an NS5B RNA polymerase inhibitor. This 3D regimen, dosed with ribavirin (RBV) in treatment-naive and -experienced HCVinfected genotype 1 (GT1) patients, has demonstrated SVR12 rates of 96% after 12…

On-Treatment Viral Response To MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV-Coinfected Patients

Background: The combination of MK-5172 (a highly potent second-generation HCV NS3/4 protease inhibitor) and MK-8742 (a highly potent HCV NS5A replication complex inhibitor) has demonstrated a high barrier to resistance. In part A of C-WORTHY, 62 of 63 treatment-naive, noncirrhotic patients with chronic HCV GT1 infection treated for 4-12 weeks with this combination } ribavirin…

Safety and Efficacy of IFN-free Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients

Background: Long-term outcome in HCV/HIV-coinfected subjects undergoing liver transplantation (LT) relies on the management of HCV recurrence. Currently available peg-IFN-based therapies are associated to high toxicity and low antiviral efficacy, leading to worse outcomes in comparison to HCV monoinfected subjects. Methodology: To describe for the first time the on-treatment safety and efficacy of the combination…